“…Increased serum levels of monoclonal IgLC are generally associated with malignant clonal B cell proliferation as seen in multiple myeloma and related proliferative disorders, and may be used as a biomarker [7,8]. Moreover, polyclonal IgLC levels are increased markedly in various inflammatory and autoimmune disorders, including multiple sclerosis [9], rheumatoid arthritis [10] and systemic lupus erythematosus [11,12], as well as in cancer [10], AIDS [13] and diabetes mellitus [14,15]. Increased IgLC levels often correlate with disease severity and can be ascribed to increased immune activity [10,16,17].…”